Vicki Moore, PhD

Contributing Writer https://www.hematologyadvisor.com

Vicki Moore, PhD, is a freelance medical writer for Hematology Advisor. Vicki received her PhD in biology from Arizona State University, where her research emphasized molecular biology, biochemistry, and metabolic engineering. She also has experience with predictive analytics and is intrigued by its applications to medicine. Vicki has been a medical writer, focusing on areas of hematology and oncology, among other specialties, since late 2017. You can find her on Linkedin at linkedin.com/in/vicki-moore-93950913

All articles by Vicki Moore, PhD

Anemia

Hemoglobin Thresholds for Transfusion in Preterm Infants With Anemia

Vicki Moore, PhD

January 21, 2021

Study results suggest that a higher hemoglobin threshold may lead to more transfusions for preterm infants with anemia but without improving outcomes.

Myelodysplastic Syndromes

Durable Erythroid Response With Lenalidomide, Epoetin Alfa in Refractory Myelodysplastic Syndromes

Vicki Moore, PhD

January 21, 2021

A phase 3 trial suggests higher responses when epoetin alfa is added to lenalidomide in treatment of erythropoietin-refractory myelodysplastic syndromes.

Bleeding Disorders

Evaluation of Bleeding Events in Women and Girls With Hemophilia

Vicki Moore, PhD

January 20, 2021

A team of investigators evaluated clinical characteristics, hemostasis management, and clinical outcomes of bleeding events in women and girls with hemophilia.

Thrombotic Disorders

von Willebrand Factor Plasma Levels May Affect Future Venous Thromboembolism Risk

Vicki Moore, PhD

January 20, 2021

A population-based analysis suggested that plasma levels of von Willebrand factor may be a potential biomarker for the future risk of incident venous thromboembolism.

Anemia

Metabolic Irregularities of Tryptophan and Serotonin Linked to Morbidity in Fanconi Anemia

Vicki Moore, PhD

January 19, 2021

A new study explores disruption of tryptophan metabolism, manifesting as dysregulation of serotonin metabolism, in patients with Fanconi anemia.

Myeloma

Cost-Effectiveness of First- vs Second-Line Daratumumab in Multiple Myeloma

Vicki Moore, PhD

January 19, 2021

Study results suggest that the cost-effectiveness of daratumumab use may be lower with first- vs second-line therapy of transplant-ineligible multiple myeloma.